This is a copy of the March 24th edition of our weekly Newsletter, which we have been publishing since October 2015.
The strong growth prospects for the cannabis industry have encouraged some companies with operating histories outside of it to begin to embrace it. This week, CVS announced that it will be selling topical CBD products in eight states, a move that was more exciting for CBD product manufactures than for CVS, at least as measured by the stock market reaction. Of course, a massive company like CVS is not likely to see its revenue or earnings impacted significantly, but there are many examples of companies that are transitioning towards cannabis.
Some of the more recent and better known entries that have real operations in the cannabis industry include Scotts Miracle-Gro, which has a large ancillary business, and Village Farms, which owns half of a Canadian LP and is set to begin hemp operations in the U.S. Lesser known but on a similar path are tobacco-focused 22nd Century Group and Pyxus International, and Alberta liquor retailer Alcanna, which has opened five cannabis stores in Alberta and soon one in Ontario.
While many cannabis investors would prefer to invest in a pure-play, it is possible that these transitional plays can work out very well. Village Farms, for example, has increased 1060% since announcing its JV in June 2017 despite minimal cannabis revenue to date. At the same time, despite its heavy M&A activity that now leaves it reasonably leveraged to cannabis, Scotts Miracle-Gro hasn’t performed well. Alcanna has dropped 55% since Aurora Cannabis invested over C$100 million into it in February 2018.
Not a week goes by, it seems, that some company that hasn’t ever accomplished much of anything is suddenly a cannabis company, and we suggest that our readers approach these situations with skepticism. Truth be told, though, 22nd Century Group, Alcanna, Pyxus and Village Farms didn’t exactly offer stellar operating performance or track records of substantial shareholder value creation, yet we believe that investors should at least explore these types of situations.
When evaluating a company entering the industry from the outside, there are a few key questions to address:
- Does it make sense?
- Is management qualified or capable?
- Does it have access to necessary capital?
- Can the cannabis operations move the needle?
- Can the valuation be justified?
Alcanna, who isn’t a client of New Cannabis Ventures, looks like it merits attention as we think it answers the questions above well. Additionally, the market seems to be largely unaware of the story. In a nutshell, the company is in the midst of a turnaround in its core alcohol retail business and posted 7% same-store sales growth in Q4, its best performance in years and despite a soft economy in Alberta. The company is at a breakeven with respect to operational cash flow and has access to capital to fund CapEx for its core business and its cannabis operations. The stock trades at just 1.6X tangible book value, with a market cap of about C$194 million. It seems like CEO Jamie Burns had it right on their recent conference call when he suggested that the cannabis operations are essentially free. For comparison, we note that retailers Westleaf and Fire and Flower sport market caps of C$352 million and C$234 million, respectively.
We expect to see more companies enter the cannabis industry from a position of already being operational outside of it, and some of these new entrants may create value. It’s important, in our view, for investors to get a handle on their non-cannabis business, as for many of these companies, cannabis could be the tail trying to wag the dog. Finally, investors should be very careful not to put cannabis valuations on non-cannabis operations.
CB2 Insights, which began trading publicly on the Canadian Securities Exchange earlier this month and has a mission to mainstream medical cannabis into traditional healthcare, generated revenue in the first three quarters of 2018 in excess of C$8 million from its clinic operations
To learn more about CB2 Insights, a client of New Cannabis Ventures, visit the company’s Investor Dashboard that we maintain on its behalf and click the blue Follow Company button in order to stay up to date with their progress.
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:
- Cannabis REIT Treehouse Raises $45.5 Million
- Canopy Growth Extends American Hemp Reach with Acquisition
- Cresco Labs Enters Florida Medical Cannabis Market with $120 Million Acquisition
- Curaleaf to Buy Nevada’s Acres Cannabis for $70 Million
- Curaleaf Reports $32 Million Revenue in Q4
- DionyMed Brands to buy Los Angeles Cannabis Operations for $19 Million
- Gotham Green to Invest $250 Million into MedMen
- Greenlane to Conduct NASDAQ IPO Underwritten by Cowen and Canaccord
- Exclusive: Harvest One is Taking its Health and Wellness Strategy Global
- Guest Post: How Cannabis Stock Promoters are Taking Advantage of Investors and Operators
- iAnthus Capital Sells $35 Million Notes Convertible at US$5.92 to Three Investors
- Exclusive: Jamaican Medical Cannabis Company Jacana Sees Big Opportunity in Brand Provenance
- Multi-State Cannabis Operator Cansortium Raises $56 Million Ahead of Public Trading
- RBC to Lend Eve & Co. $18.7 Million to Construct Cannabis Greenhouse
- Tilray Q4 Revenue Grows 204% to $15.5 Million
- Valens GroWorks Raises $30 Million Selling Units at $2.95
For investors interested in the cannabis industry and for operators looking to tell their differentiated stories, there is no better event than the Benzinga Cannabis Capital Conference. After highly successful events in Miami and Toronto in recent months, Benzinga returns to Toronto at the Fairmont Hotel next month, and we are excited to partner with them again. For high quality companies interested in presenting, please email PatrickLane@Benzinga.com to learn about the many opportunities available.
Tickets are limited! New Cannabis Ventures should use code “NCV” to ensure a seat for a 20% discount. We look forward to seeing you there!
To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.
Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer a family of indices to track Canadian licensed producers as well as the American Cannabis Operator Index.
View the Public Cannabis Company Revenue Tracker, which ranks the top revenue producing cannabis stocks that generate industry sales of more than $2.5m per quarter.
Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.
Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.
Consider subscribing to 420 Investor, Alan’s comprehensive stock due diligence platform since 2013 for more in-depth information and market intelligence about the publicly traded cannabis sector.
Find your place in the cannabis industry by visiting our Careers and Jobs Page and learn which companies are hiring aggressively.
Alan & Joel